Education
About Us
Working with TipRanks
Follow Us
Gain Therapeutics (GANX)
NASDAQ:GANX
Total Valuation
Gain Therapeutics has a market cap or net worth of $45.85M. The enterprise value is $48.87M.
Market Cap$45.85M
Enterprise Value$48.87M
Share Statistics
Gain Therapeutics has 27.79M shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding27.79M
Owened by Insiders4.90%
Owened by Instutions3.17%
Financial Efficiency
Gain Therapeutics’s return on equity (ROE) is -2.78 and return on invested capital (ROIC) is -249.60%.
Return on Equity (ROE)-278.10%
Return on Assets (ROA)-168.36%
Return on Invested Capital (ROIC)-249.60%
Return on Capital Employed (ROCE)-247.80%
Revenue Per Employee$2,817.391
Profits Per Employee-$928,997.043
Employee Count23
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Gain Therapeutics is -2.42. Gain Therapeutics’s PEG ratio is 0.05.
PE Ratio-2.42
PS Ratio0.00
PB Ratio6.73
Price to Fair Value6.73
Price to FCF-2.20K
Price to Operating Cash Flow0.00
PEG Ratio0.05
Income Statement
In the last 12 months, Gain Therapeutics had revenue of $64.80K and earned -$21.37M in profits. Earnings per share was -$1.10.
Revenue$64.80K
Gross Profit$90.00
Operating Income-$21.43M
Pretax Income-$21.32M
Net Income-$21.37M
EBITDA-21.37M
Earnings Per Share (EPS)-1.10
Cash Flow
In the last 12 months, operating cash flow was -$21.08M and capital expenditures -$21.57K, giving a free cash flow of -$21.10M billion.
Operating Cash Flow-$21.08M
Free Cash Flow-$21.10M
Free Cash Flow per Share-$0.76
Dividends & Yields
Gain Therapeutics pays an annual dividend of , resulting in a dividend yield of
Dividend Per Share
Dividend Yield
Payout Ratio
Free Cash Flow Yield-0.05%
Earnings Yield-41.30%
Stock Price Statistics
Beta1.30
52-Week Price Change-45.63%
50-Day Moving Average2.12
200-Day Moving Average1.81
Relative Strength Index (RSI)37.75
Average Volume (3m)261.38K
Important Dates
Gain Therapeutics upcoming earnings date is May 7, 2025, After Close.
Last Earnings DateMar 27, 2025
Next Earnings DateMay 7, 2025
Ex-Dividend Date―
Financial Position
Gain Therapeutics as a current ratio of 2.97, with Debt / Equity ratio of 0.03
Current Ratio2.97
Quick Ratio2.97
Debt to Market Cap<0.01
Net Debt to EBITDA0.50
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Gain Therapeutics has paid $46.58K in taxes.
Income Tax$46.58K
Effective Tax Rate-2.70%
Enterprise Valuation
Gain Therapeutics EV to EBITDA ratio is -1.93, with an EV/FCF ratio of -1.75K.
EV to Sales0.00
EV to EBITDA-1.93
EV to Free Cash Flow-1.75K
EV to Operating Cash Flow0.00
Balance Sheet
Gain Therapeutics has $12.05M in cash and marketable securities with $769.41K in debt, giving a net cash position of -$11.28M billion.
Cash & Marketable Securities$12.05M
Total Debt$769.41K
Net Cash-$11.28M
Net Cash Per Share-$0.41
Tangible Book Value Per Share$0.32
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Gain Therapeutics is $8.00, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$8.00
Price Target Upside406.33%
Analyst ConsensusStrong Buy
Analyst Count4
Revenue Growth Forecast-100.00%
EPS Growth Forecast44.28%